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Abstract. 
 
The immunosuppressive and antiinflamma-
tory actions of glucocorticoid hormones are mediated 
by their transrepression of activating protein-1 (AP-1) 
 
and nuclear factor-kappa B (NF
 
k
 
B) transcription fac-
 
tors. Inhibition of the c-Jun NH
 
2
 
-terminal kinase (JNK) 
signaling pathway, the main mediator of AP-1 activa-
tion, has been described in extracts of hormone-treated 
cells. Here, we show by confocal laser microscopy, enzy-
matic assays, and immunoblotting that the synthetic 
glucocorticoid dexamethasone inhibited tumor necrosis 
factor 
 
a 
 
(TNF-
 
a
 
)–induced phosphorylation and activa-
tion of JNK in the cytoplasm and nucleus of intact 
HeLa cells. As a result, c-Jun NH
 
2
 
-terminal domain 
phosphorylation and induction were impaired. Dexa-
methasone did not block the TNF-
 
a
 
–induced JNK nu-
clear translocation, but rather induced, per se, nuclear 
accumulation of the enzyme. Consistently with previ-
ous findings, a glucocorticoid receptor mutant 
(GRdim), which is deficient in dimerization, DNA 
binding, and transactivation, but retains AP-1 transre-
pressing activity, was as efficient as wild-type GR in me-
diating the same effects of dexamethasone on JNK in 
transfected Cos-7 cells. Our results show that glucocor-
ticoids antagonize the TNF-
 
a
 
–induced activation of 
AP-1 by causing the accumulation of inactive JNK 
without affecting its subcellular distribution.
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Introduction
 
Glucocorticoid hormones have many important regulatory
roles in the organism. Their activities are exerted through
the control of genes via three mechanisms: direct tran-
scriptional regulation, indirect transcriptional regulation
through interference with other transcription factors, and
posttranscriptional effects (Vayssière et al., 1997; Resche-
Rigon and Gronemeyer, 1998). Glucocorticoids are widely
 
used to treat inflammatory and autoimmune disorders. Many
genes involved in immune and inflammatory responses
have regulatory sites for activating protein-1 (AP-1)
 
1
 
 and
 
nuclear factor kappa B (NF
 
k
 
B) transcription factors. There
is evidence that the immunosuppressive and antiinflam-
matory actions of glucocorticoid hormones are mediated
 
by their transrepression of AP-1 and NF
 
k
 
B
 
 
 
(Vayssière et al.,
1997; Göttlicher et al., 1998; Karin, 1998; Resche-Rigon
and Gronemeyer, 1998). Transrepression of AP-1 is also a
key feature of the antitumor activity of glucocorticoids in
mouse skin (Tuckermann et al., 1999). This is emphasized
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Abbreviations used in this paper:
 
 AP-1, activating protein-1; Dex, dexa-
methasone; GR, glucocorticoid receptor; GRdim, GR mutant deficient in
dimerization; GRwt, GR wild-type; Hsp70, heat shock protein 70; JNK,
 
c-Jun NH
 
2
 
-terminal kinase; TNF-
 
a
 
, tumor necrosis factor-
 
a
 
.
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by the finding that, in contrast to glucocorticoid receptor
 
(
 
GR
 
2
 
/
 
2
 
) animals, 
 
GR
 
dim
 
 mutant mice expressing a mutant
hormone receptor (GRdim) that is deficient in dimeriza-
tion, DNA binding, and transactivation, but retains AP-1
transrepressing activity, are viable (Reichardt et al., 1998).
In addition, GRdim mediates repression of AP-1-depen-
dent genes in mouse skin (Tuckermann et al., 1999). More-
over, defective AP-1 repression may explain resistance to
the antiinflammatory effect of glucocorticoids in asthma
patients (Adcock et al., 1995).
AP-1 is a group of dimeric factors constituted by mem-
bers of the c-Jun and c-Fos families of protooncogenic
products (Karin et al., 1997). AP-1 is activated by mito-
gens, oncoproteins, proinflammatory cytokines, such as tu-
mor necrosis factor 
 
a 
 
(TNF-
 
a
 
) and interleukin-1, and ul-
traviolet radiation. c-Jun, the main component of AP-1, is
activated by NH
 
2
 
-terminal phosphorylation on serines 63
and 73 (Ser
 
63/73
 
) by members of the c-Jun NH
 
2
 
-terminal
Kinase (JNK) family (Minden and Karin, 1997). Interac-
tions between hormone-activated receptors and AP-1,
competition for limiting amounts of common transcrip-
tional coactivators, such as cAMP response element-bind-
ing protein (CREB)-binding protein (CBP), or binding to
DNA have been proposed to explain the mutual antago-
nism between hormones acting through nuclear receptors
and AP-1 (for a review see Göttlicher et al., 1998). In addi-
tion, we and others have recently described the inhibition
of the JNK signaling pathway, and hence of c-Jun phos-
phorylation and AP-1 activation, in extracts of hormone-
treated cells
 
 
 
(Caelles et al., 1997; Swantek et al., 1997;
González et al., 1999; Lee et al., 1999; Srivastava et al.,
1999; Ventura et al., 1999). Remarkably, the generation of
transgenic mice harboring a mutant allele of c-Jun with
Ser
 
63/73
 
 mutated to alanines has shown that NH
 
2
 
-terminal
phosphorylation of c-Jun is critical for stress-induced ap-
optosis and cellular proliferation in vivo (Behrens et al.,
1999).
To gain insight into the mechanism of AP-1 interference
by hormone-activated nuclear receptors, we have ad-
dressed the following questions. Does the synthetic gluco-
corticoid dexamethasone (Dex) inhibit JNK phosphoryla-
tion/activation in intact cells? Can Dex affect nuclear
translocation of JNK? And, what is the mechanism of hor-
mone-activated GR and what is its primary target?
 
Materials and Methods
 
Cell Culture and Transfections
 
HeLa and Cos7 cells were grown in DME supplemented with 10% FCS.
Media, tissue culture reagents, and FCS were purchased from GIBCO
BRL. Cells were serum starved by changing the culture medium to DME
supplemented with 0.5% FCS 16 h before treatment. Cos-7 cells were
transfected with 3 
 
m
 
g of plasmid encoding HA-JNK (pCDNA3-JNK1)
and 0.4 
 
m
 
g of those encoding either GRwt (pSB-hGR) or GRdim (pSB-
 
hGR(A458T)), or with the empty vector (pRSh
 
2
 
R
 
2
 
; donated by Dr.
A.C.B. Cato, Karlsruhe, Germany). Treatments: HeLa or Cos-7 cells (24–
48 h after transfection) were pretreated with Dex (1 
 
m
 
M) or vehicle (etha-
nol) for 45 min. This period was chosen because of previous studies show-
 
ing that it is sufficient for maximum inhibition of JNK activation by TNF-
 
a
 
(Caelles et al., 1997). After Dex pretreatment, TNF-
 
a
 
 (10 ng/ml) or its ve-
hicle (ethanol) was added to the cells. Thus, TNF-
 
a
 
 
 
1
 
 Dex cells were incu-
bated with Dex for 45 min plus the indicated period of TNF-
 
a
 
 stimulation.
Dex-alone control cells were incubated with hormone during the pretreat-
ment and throughout for the period of stimulation.
 
Immunocytochemistry
 
HeLa and Cos7 cells were rinsed twice in PBS, fixed with 3.7% paraform-
aldehyde in PBS for 15 min at room temperature, permeabilized with
0.5% Triton X-100 for 15 min, and were then treated with 0.1 M glycine in
PBS for 15 min. The nonspecific sites were blocked by incubation with
PBS containing 1% BSA or goat serum for 30 min at room temperature.
Cells were then washed in PBS containing 0.05% Tween-20 for 5 min and
incubated with the primary antibodies diluted in PBS for 1 h at room tem-
perature or overnight at 4
 
8
 
C.
The following primary antibodies were used: rabbit polyclonal or
mouse monoclonal anti–c-Jun phosphorylated on serine-63 (New England
Biolabs, Inc., 9261S; or Santa Cruz Biotechnology, Inc., sc-822), rabbit
polyclonal anti–c-Jun (Oncogene Research, PC06), mouse monoclonal
against human JNK1 (BD PharMingen, 15701A), mouse monoclonal anti-
JNK1 phosphorylated on threonine-183 and tyrosine-185 (Santa Cruz
Biotechnology, Inc., sc-6254), and rabbit polyclonal anti-GR (Santa Cruz
Biotechnology, Inc., sc-1003). The cells were incubated for 45 min with
one of the following secondary antibodies: Texas red (TxR)-conjugated
goat anti–rabbit (Jackson ImmunoResearch or Vector), FITC-conjugated
goat anti–rabbit (Jackson ImmunoResearch), and TxR-conjugated goat
anti–mouse (Jackson ImmunoResearch). To amplify the phospho-JNK
and JNK1 staining, anti-mouse Ig-digoxigenin, F(ab
 
9
 
)
 
2
 
-fragment, followed
by antidigoxigenin-rhodamine (Boehringer), or biotinylated anti-mouse,
followed by streptavidin-rhodamine (Jackson ImmunoResearch), second-
ary antibodies were used. Double immunofluorescence with anti-GR and
antiphospho-JNK or anti-JNK1 was performed on samples of Cos7 cells
transfected with wild-type GR (GRwt) or GRdim.
 
Confocal Microscopy and Quantification
 
Confocal microscopy was performed with an MRC-1024 laser scanning
microscope (BioRad), equipped with an Axiovert 100 invert microscope
 
(ZEISS), and using excitation wavelengths of 488 nm (for FITC) and 543 nm
(for TxR). To measure fluorescence intensity in cell cultures treated with
TNF-
 
a
 
 or preincubated with Dex before TNF-
 
a
 
, 30 cells without prior se-
lection of each culture were analyzed by laser spectroscopy performed
with the confocal microscope and using a Plan-Apochromat 63x/1.4 oil im-
mersion objective. The selection of rectangular regions of interest in the
nucleus, excluding nucleoli, the adjustment of the confocal settings (iris,
gain, black level), the same for each cell series, and the quantification of
fluorescence intensities on a grey scale (0–255) was performed following
the procedure of Leclerc et al. (1998). After correcting nuclear (N) and cy-
toplasmic (C) fluorescence intensities for background, the nucleocytoplas-
mic ratio ( ) for the JNK signal was calculated as de-
scribed (Leclerc et al., 1998). Data were analyzed by Microsoft Excel on a
Macintosh computer.
 
Subcellular Fractionation
 
To prepare whole-cell extracts, the monolayers were washed twice in PBS
 
and the cells were lysed by incubation in RIPA buffer (150 mM NaCl,
 
1.5 mM MgCl
 
2
 
, 10 mM NaF, 10% glycerol, 4 mM EDTA, 1% Triton
X-100, 0.1% SDS, 1% deoxycholate, 50 mM Hepes, pH 7.4, plus PPIM [25
mM 
 
b
 
-glycerophosphate, 1 mM Na
 
3
 
VO
 
4
 
, 1 mM PMSF, 10 
 
m
 
g/ml leupep-
tin, 10 
 
m
 
g/ml aprotinin]) for 15 min on ice followed by centrifugation at
 
13,000 rpm for 10 min at 4
 
8
 
C. For subcellular fractionation, cells were
lysed in nuclear precipitation buffer (NPB: 10 mM Tris HCl, pH 7.4, 2 mM
MgCl
 
2
 
, 140 mM NaCl, plus PPIM) supplemented with 0.1% Triton X-100
by incubating on ice for 10 min. The lysate was layered onto 50% wt/vol
sucrose/NPB and centrifuged at 13,000 rpm for 10 min. Supernatants were
taken as cytosolic fraction. Pellets (nuclei) were washed with NPB and ex-
 
tracted with Dignam C buffer (20 mM Hepes, pH 7.9, 25% glycerol, 0.42 M
NaCl, 1.5 mM MgCl
 
2
 
, 0.2 mM EDTA, 1 mM DTT, plus PPIM) to obtain
the nuclear fraction.
 
Immune Complex Kinase Assay
 
JNK was immunoprecipitated from each subcellular fraction using 0.4 
 
m
 
g
of an anti-JNK antibody (sc-474 from Santa Cruz Biotechnology, Inc.).
 
JNK activity in the immunocomplexes was assayed by incubation with 1 
 
m
 
g
glutathione S–transferase–c-Jun1-79 (GST-c-Jun) as substrate in the pres-
 
ence of 20 
 
m
 
M cold ATP and 1 
 
m
 
Ci of 
 
g
 
[
 
32
 
P]ATP as described (Caelles et al.,
1997).
R N C–( ) N C+( )⁄=
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Western Blotting
 
JNK, phosphorylated JNK, and MEK-1 were detected in subcellular ex-
tracts by immunoblotting using the specific antibodies sc-474 (Santa Cruz
Biotechnology, Inc.), V7931 (Promega), and sc-219 (Santa Cruz Biotech-
nology, Inc.), respectively. Histone H1
 
0 
 
was detected using an mAb do-
nated by Prof. A. Alonso (Deutches Krebsforschung Zentrum, Heidel-
berg). Western blots were performed and developed using the ECL detec-
tion system (Amersham Pharmacia Biotech) using either HRP-conju-
gated anti-rabbit (for anti-JNK, antiphospho-JNK, and anti-MEK-1) or
HRP-conjugated anti-mouse (for antihistone H1
 
0
 
) antibodies (ICN).
 
Results
 
Glucocorticoids Inhibit both Nuclear Increase in
NH
 
2
 
-terminal Phosphorylated and Total c-Jun, and in 
Phosphorylated/Activated JNK in HeLa Cells
 
To study whether glucocorticoids inhibit phosphorylation
of c-Jun NH
 
2
 
-terminal domain in intact cells in vivo, we
analyzed by confocal laser scanning microscopy the immu-
nofluorescence of HeLa cells incubated with an antibody
against c-Jun protein phosphorylated on serine-63 (hereaf-
ter referred to as phospho-c-Jun) upon treatment with
TNF-
 
a
 
. No signal over background was found in cells
treated with vehicle or Dex alone (Fig. 1 A, a and b).
Upon TNF-
 
a
 
 treatment, an intense punctate staining against
a more diffuse signal appeared throughout the nucleus
(except the nucleoli), whereas the cytoplasm remained
negative (Fig. 1 A, c). The increase in phospho-c-Jun in-
duced by 30-min treatment with TNF-
 
a
 
 was efficiently in-
hibited in Dex-treated cells (Fig. 1 A, c and d). Dex re-
duced the level of nuclear phospho-c-Jun induced by TNF-
 
a
 
in HeLa cells by 
 
z
 
60% (Fig. 1 B). Unstimulated vehicle-
and Dex-treated cells showed a similar low nuclear stain-
ing when an antitotal c-Jun antibody was used (Fig. 1 C, a
and b). Upon TNF-
 
a
 
 treatment, a strong nucleoplasmic
immunolabeling was observed (Fig. 1 C, c). In agreement
with previous data (Caelles et al., 1997), Dex also inhibited
the increase in total c-Jun protein caused by the transcrip-
tional activation of the c-
 
jun
 
 gene in response to TNF-
 
a
 
(Fig. 1 C, c and d). Computer-assisted quantification re-
vealed a 40% inhibition in TNF-
 
a
 
 
 
1
 
 Dex cells with respect
to cells treated with TNF-
 
a
 
 alone (Fig. 1 D).
c-Jun phosphorylation is a consequence of the TNF-
 
a
 
–induced dual phosphorylation and subsequent activa-
tion of JNK and its concomitant translocation into the cell
nucleus (Karin et al., 1997; Minden and Karin, 1997). There-
fore, we next examined whether the reduction in phospho-
c-Jun levels could be due to the inhibition of JNK activity
within the nucleus. Immunofluorescence analysis by con-
focal microscopy using a specific antiphospho-JNK antibody
showed that Dex reduced the level of cytosolic (56%) and
nuclear (71%) phospho-JNK induced by TNF-
 
a
 
 (Fig. 2, A
and B). This result was confirmed by immunoblotting
analysis (Fig. 2 C). To check whether this effect of Dex
correlated with a decrease in enzymatic activity in both
cellular compartments, we measured JNK activity in cyto-
solic and nuclear fractions. In agreement with immunoflu-
orescence and immunoblotting data, Dex pretreatment led
to significant reductions in JNK activity in both cytosolic
and nuclear fractions (Fig. 2 D), which were consistent
with the lower levels of nuclear phospho-JNK (Fig. 2, A
and B). In turn, these data are consistent with the reduc-
Figure 1. Inhibition by Dex of c-Jun phosphorylation and induc-
tion in TNF-a–treated HeLa cells. A, Confocal laser scanning mi-
croscopy analysis of HeLa cells incubated with a polyclonal anti-
body against c-Jun phosphorylated on serine-63: a, unstimulated,
vehicle-treated cells; b, cells treated with 1 mM Dex alone; c,
TNF-a cells, preincubated with vehicle for 45 min and then
treated with 10 ng/ml TNF-a for 30 min; d, TNF-a 1 Dex cells,
preincubated with Dex for 45 min and then treated also with 10
ng/ml TNF-a for an additional 30 min. B, Quantification of the
inhibition by Dex of the TNF-a–induced nuclear phospho-c-Jun
average fluorescence intensity in HeLa cells. C, Confocal micros-
copy analysis of the immunofluorescence of HeLa cells incubated
with an anti–c-Jun antibody: a–d are as in A. D, Quantification of
the inhibition by Dex of the TNF-a–induced nuclear c-Jun aver-
age fluorescence intensity in HeLa cells. Bars, 15 mm.
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Figure 2. Inhibition by Dex
of TNF-a–induced JNK
phosphorylation and enzy-
matic activity. A, Confocal
microscopy analysis of HeLa
cells incubated with an mAb
against JNK1 phosphory-
lated on threonine-183 and
tyrosine-185: a–d are as in
Fig. 1 A, and are described in
Materials and Methods. Bar,
15 mm. B, Quantification of
the inhibition by Dex of the
TNF-a–induced phospho-JNK
average fluorescence inten-
sity in the cytoplasm and nu-
cleus of HeLa. C, Western
blot analysis of the amount
of phosphorylated JNK pre-
sent in HeLa cells upon
TNF-a (10 ng/ml) addition to
cultures preincubated with
vehicle (2) or 1 mM Dex. A
rabbit polyclonal antiphos-
pho-JNK antibody was used.
The effect of Dex on the in-
crease of phosphorylated JNK
caused by TNF-a is indi-
cated. Filters were reincu-
bated with a rabbit poly-
clonal antibody against total
JNK for loading control.
Quantification of the results
obtained in three indepen-
dent experiments (mean val-
ues 6 SD) is indicated. D, In-
hibition by Dex of JNK
activity in nuclear and cyto-
solic fractions of TNF-
a–treated HeLa cells. Cells
were treated with vehicle (2)
or 1 mM Dex 45 min before
addition of 10 ng/ml TNF-a.
At the indicated times after
TNF-a treatment subcellular
fractionation was carried out.
JNK activity in each fraction
was estimated by the im-
mune complex kinase assay.
Purity of subcellular fractions
was ensured by incubation
with polyclonal anti-MEK-1
and monoclonal antihistone
H10 antibodies. Quantifica-
tion of the results (mean val-
ues) obtained in two experi-
ments is shown below.
 
Figure 3
 
. Lack of effect of Dex on the TNF-
 
a–induced nuclear accumulation of JNK in HeLa cells. A, Confocal microscopy analysis of
HeLa cells incubated with an mAb against total JNK. The signal was amplified by using a biotin–streptavidin system as described in Ma-
terials and Methods. Cells were treated with: a, vehicle; b, TNF-a; and c, TNF-a 1 Dex, as described in Fig. 1 A. Bar, 15 mm. The values
of the ratio , as defined by Leclerc et al. (1998), estimating the change in subcellular distribution are shown below
the micrographs. Quantification of the TNF-a–induced nuclear accumulation of JNK in cells treated or not with Dex (right). B, Western
blot analysis of the amount of total JNK present in cytosol or nucleus of HeLa cells upon TNF-a (10 ng/ml) addition to cultures preincu-
bated with vehicle (2) or 1 mM Dex for 45 min. A rabbit polyclonal anti-JNK antibody and a secondary HRP-conjugated anti-rabbit
antibody were used. Antibodies against MEK-1 and histone H10 were used to ensure purity of subcellular fractions. Quantification of
the results (nucleus) is indicated: black columns, TNF-a cells; white columns, TNF-a 1 Dex cells. C and D, Dex alone induces JNK nu-
clear accumulation. C, Confocal microscopy analysis of HeLa cells incubated with an antibody against total JNK. Signal was amplified
as before: a, vehicle-treated cells; b, cells treated with 1 mM Dex for 21 min; c, cells treated with 1 mM Dex for 45 min. Bar, 15 mm. R val-
ues are shown below the micrographs. D, Quantification of the Dex-induced nuclear accumulation of JNK is shown. Western blot anal-
R N C–( ) N C+( )⁄=
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ysis of the amount of total JNK present in cytosol (30 mg) or nucleus (50 mg) of HeLa cells upon incubation with vehicle (2) or 1 mM
Dex for the indicated times. The relative levels of total JNK present in a representative experiment in each subcellular fraction are indi-
cated. Purity of subcellular fractions was checked using antibodies against MEK-1 and histone H10 as before. Quantification of the re-
sults obtained in three independent experiments (mean values 6 SD) is indicated. E, Lack of effect of Dex alone on JNK activity in un-
stimulated cells. Results obtained in cytosolic and nuclear fractions are shown. JNK activity in each subcellular fraction of HeLa cells
incubated as indicated with vehicle (2), 1 mM Dex, 10 ng/ml TNF-a, or both agents was measured by the immune complex kinase assay.
The amount of JNK present in each extract was estimated by Western blot using a polyclonal antitotal JNK antibody.
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tion of phospho-c-Jun in Dex-treated cells when stimu-
lated with TNF-a (Fig. 1 A). Verification that nuclear pro-
teins did not leak into the cytosolic fractions during the
fractionation process was obtained through subsequent
hybridization of Western membranes to detect histone
H10, which localizes exclusively in the nucleus. Con-
versely, MEK-1 was detected only in cytosolic fractions
(Fig. 2 D).
Glucocorticoids Do Not Inhibit the TNF-a–induced 
Nuclear Accumulation of JNK
We used antibodies against total JNK to test the possibil-
ity that the inhibitory effect of Dex on the nuclear levels of
phospho-JNK and JNK activity could be the consequence
of a reduction in the nuclear content of this enzyme. In un-
stimulated HeLa cells, JNK immunoreactivity was dif-
fusely distributed in the cytosol and nucleus (Fig. 3 A, a).
TNF-a induced the nuclear accumulation of the enzyme,
which was unchanged by Dex treatment (Fig. 3 A, b and
c). Using two distinct antibodies (anti-JNK1/JNK3 sc-474
and anti-JNK1 15701A), the same increase (five- to six-
fold) in fluorescence was found in the nucleus of TNF-
a–treated cells, irrespective of Dex pretreatment (Fig. 3
A, right), whereas cytoplasmic fluorescence did not change
significantly upon any treatment (not shown). Measure-
ment of JNK translocation by immunoblotting of subcellu-
lar fractions revealed that JNK was predominantly cytoso-
lic in unstimulated HeLa cells, and confirmed that TNF-
a induced a similar increase in nuclear JNK content, irre-
spective of pretreatment with Dex (Fig. 3 B). A large
amount of JNK remained in the cytosol even in TNF-
a–treated cells. The lack of significant differences in cyto-
solic JNK can be explained by the fact that JNK is abundant
in the cytosol (z30-fold higher than in the nucleus in un-
stimulated cells) and therefore only a small fraction of cy-
tosolic JNK is mobilized to the nucleus. The apparent dis-
crepancy between the levels of extranuclear JNK content
observed by immunoblotting and immunofluorescence may
be explained by the fact that the image obtained by confo-
cal microscopy corresponds to a cellular slice, whereas im-
munoblotting of subcellular fractions allows a more pre-
cise estimation of JNK content in each fraction as takes
into account their total size. It should be kept in mind that
a minor degree of protein leakage during cellular fraction-
ation and/or differences in fluorescence signal due to vari-
ations in epitope accessibility and microenvironment can-
not be ruled out. Dex alone also caused a slight, but
reproducible, accumulation of JNK in the nucleus (Fig. 3
C). This effect was progressive and led to a 2–2.5-fold in-
crease in nuclear JNK content (Fig. 3 D). To rule out the
possibility that Dex could affect basal JNK activity by it-
self, we performed JNK assays in cytosolic and nuclear
fractions of HeLa cells upon hormone addition. As ex-
pected, Dex did not induce JNK activity, but inhibited the
activation of this enzyme by TNF-a (Fig. 3 E). The inhibi-
tion was simultaneous in cytosol and nucleus, with kinetics
compatible with that of nuclear entry of hormone-bound
GR (Htun et al., 1996). These results show that Dex alone
caused an accumulation of inactive JNK in the nucleus and
that Dex treatment did not affect the subcellular distribu-
tion of JNK induced by TNF-a.
Mechanism of JNK Inhibition by
Hormone-activated GR
We found no evidence of interaction between activated,
hormone-bound GR and JNK when we coimmunoprecipi-
tated these two proteins from HeLa cell extracts (not
shown). In view of recent reports (Gabai et al., 1997;
Mosser et al., 1997) that overexpression of the heat-shock
protein 70 (Hsp70) inhibits JNK activity, we also studied
whether Hsp70 mediates the inhibitory action of Dex-
bound GR. Western blots of separate cytosolic and nu-
clear fractions showed that Dex treatment did not affect
the cellular content of Hsp70, at least during the period
relevant for the inhibition of JNK (not shown). Likewise,
no changes in Hsp70 levels in either cellular fraction were
found upon TNF-a addition to control or Dex-treated
HeLa cells (not shown). In addition, we examined whether
Dex treatment affected the amount of Hsp70 that is bound
to JNK. However, the highly unspecific binding of this
protein (even to agarose beads) precluded this analysis.
Next, we examined whether a mutant form of GR
(GRdim; Heck et al., 1994), which is unable to ho-
modimerize, fails to bind DNA, and cannot transactivate
GR element (GRE)-dependent promoters, could mediate
Dex-induced JNK inhibition. Upon hormone binding,
GRdim was as efficient as GRwt in inhibiting JNK activity
(Fig. 4 A). We also analyzed whether GRdim, like GRwt,
accumulates in the nucleus after Dex treatment. Both ec-
topically-expressed GRwt and GRdim translocate into the
nucleus of transfected Cos-7 cells upon Dex addition (Fig.
4 B). This result emphasizes the DNA-binding–indepen-
dent activities of GRdim and the transcription-indepen-
dent inhibition of the JNK pathway by Dex (Caelles et al.,
1997). Furthermore, it supports the link between AP-1
transrepression and JNK inhibition, and demonstrates that
monomeric hormone-bound GR can mediate this effect.
To verify that GRdim has the same effects on JNK ac-
tivity and nuclear accumulation as GRwt, we analyzed the
effects of Dex in GR-deficient Cos-7 cells that were trans-
fected with either of these two genes. As seen in Fig. 5 A,
Dex treatment of GRwt- or GRdim-transfected Cos-7
caused the same inhibition of the TNF-a–induced JNK
phosphorylation as observed in HeLa cells. Measurement
of fluorescence intensity showed a 73 and 74% inhibition
of nuclear phospho-JNK in GRwt- and GRdim-trans-
fected cells, respectively. Likewise, in both types of trans-
fected cells, Dex inhibited the increase in phospho-c-Jun
and total c-Jun (not shown). Also as in HeLa cells, the ac-
cumulation of total JNK in the nucleus was not inhibited,
but even slightly increased, by the hormone in both GRwt-
and GRdim-transfected Cos-7 cells (Fig. 5 B, b). In agree-
ment with this, Dex did not change the nuclear transloca-
tion of JNK induced by TNF-a (Fig. 5 B, c and d).
Discussion
Our results show that Dex inhibits JNK phosphorylation
and activity in intact cells, and that this effect is not due to
inhibition of the nuclear translocation of the enzyme in-
duced by TNF-a. Rather, Dex by itself can promote the
nuclear entry of inactive JNK in noninduced cells. These
results were observed in two cell types, HeLa and Cos-7,
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and extend previous observations that JNK activity was
reduced in extracts from cells treated with glucocorticoids,
retinoids, thyroid hormone, or estrogens (Caelles et al.,
1997; Swantek et al., 1997; González et al., 1999; Lee et al.,
1999; Srivastava et al., 1999; Ventura et al., 1999).
Our results differ from those reported for extracellular-
regulated kinase (ERK), which suggested that kinase phos-
phorylation was necessary to induce homodimerization and
subsequent nuclear translocation (Khokhlatchev et al., 1998).
Differences in the mechanism of translocation between ERK
and JNK, or perhaps cell type-specific differences, are also
suggested by the finding that JNK1 is translocated into the
nucleus of rat heart cells during ischemia, but that activa-
tion only takes place after reperfusion (Mizukami et al.,
1997). Our results indicate a process other than JNK nu-
clear translocation for repression by hormone-bound GR.
We had previously shown that 45-min pretreatment with
Dex is sufficient for maximum inhibition of JNK, whereas
half-maximum effect is obtained with a hormone treat-
ment of only 10 min, which is coincident with the half-time
of nuclear translocation of GR (Caelles et al., 1997). In ad-
dition, a mutant transactivation-deficient GR (LS7; Schena
et al., 1989; Helmberg et al., 1995) was found to mediate
JNK repression (Caelles et al., 1997). However, GR-LS7
mutant has been reported to keep residual transactivating
activity (Heck et al., 1997). The finding now that GRdim is
as efficient as GRwt in mediating the effects of Dex indi-
cates rapid inhibition of JNK phosphorylation even by mo-
nomeric DNA binding-deficient, Dex-bound GR, which in-
activates the enzyme in both cytosol and nucleus. This
result demonstrates that the rapid inhibition of JNK does
not require transcriptional activation by Dex, and also re-
inforces the DNA-binding independent activities of GR.
The effects of Dex have at least two possible explana-
tions: direct or indirect inhibition of JNK activation in the
cytoplasm in response to stress, and the activation of puta-
tive phosphatase(s). The negative result of the coimmuno-
precipitation approach do not rule out a direct interaction
between JNK and activated GR. Likewise attempts to
coimmunoprecipitate JNK and its substrate c-Jun have
failed, probably due to the existence of transient and/or
weak interaction (Minden and Karin, 1997), JNK and GR
might form unstable complexes that impede their coimmu-
noprecipitation by current protocols. Alternatively, they
Figure 4. Inhibition of TNF-
a–induced JNK activation by
Dex is independent of GR
dimerization, DNA binding,
and gene transactivation. A,
Mutant GRdim receptor
mediates Dex inhibition of
TNF-a–induced JNK activa-
tion in Cos-7 cells. Induction
of JNK activity by TNF-a in
Cos-7 cells cotransfected with
3 mg of plasmid encoding
HA-JNK (pCDNA3-JNK1)
and 0.4 mg of empty vector
(pRSh2R2, left) or those
encoding either GRwt
(pSB-hGR, middle) or
GRdim (pSB-hGR(A458T),
right). 24 h after transfection,
cells were treated with vehi-
cle (open circles) or 1 mM
Dex (solid circles) for 45 min.
Then, TNF-a (10 ng/ml) was
added with no medium
change, and JNK activity was
measured at the indicated
times after TNF-a addition
by the immune complex ki-
nase assay. Results from du-
plicates obtained in two sepa-
rate experiments are shown.
B, GRdim translocates into
the cell nucleus upon Dex
treatment. Cos-7 cells were
transfected with empty vec-
tor (left), or those encoding
either GRwt (pSB-hGR,
middle) or GRdim (pSB-
hGR(A458T), right) as before. 48 h after transfection cells were treated with vehicle (top micrographs) or 1 mM Dex (bottom micro-
graphs) for 45 min and localization of ectopically expressed GRwt or GRdim was analyzed by immunofluorescence using a rabbit poly-
clonal anti-GR antibody. Bar, 15 mm.
The Journal of Cell Biology, Volume 150, 2000 1206
could interact indirectly through intermediate proteins in
the frame of the large multiprotein signalosome/COP9
complexes where JNK may be associated (Wei et al., 1998;
Seeger et al., 1998). However, the signalosome-directed
c-Jun activation is independent of JNK (Naumann et al.,
1999). Regarding the second possibility, retinoids have
been reported to induce MKP-1 phosphatase accumula-
tion in nonsmall cell lung cancer cells (Lee et al., 1999).
However, we have not found MKP-1 induction by Dex in
HeLa cells (Caelles et al., 1997) and, furthermore, its ki-
netics in lung cancer cells is clearly delayed with respect to
the inhibition of JNK by Dex in our system. These results,
however, do not rule out the involvement of other phos-
phatase(s). It also remains to be determined whether JNK
itself or any upstream component of the pathway is the
primary target of hormone-activated GR. However, sev-
eral studies suggest that Dex does not inhibit the immedi-
ate upstream kinases MEKK or SEK-1 (Caelles et al., 1997;
Swantek et al., 1997; Lee et al., 1999).
Known JNK targets are mainly nuclear, such as c-Jun,
ATF-2, Elk-1, and p53 (Karin et al., 1997; Minden and
Karin, 1997; Fuchs et al., 1998). Only NFAT4 has been
proposed to be phosphorylated by JNK in the cytosol
(Chow et al., 1997). However, the presence of high levels
Figure 5. GRdim has the
same effect as GRwt on the
TNF-a–induced JNK activa-
tion/phosphorylation and ac-
cumulation into the nucleus.
Cos-7 cells were transfected
with plasmids encoding ei-
ther GRwt or GRdim as indi-
cated. 48 h after transfection,
cells were treated with: a, ve-
hicle; b, Dex alone; c, TNF-a;
or d, TNF-a 1 Dex, as de-
scribed in Fig. 1 A and Mate-
rials and Methods, and dou-
ble-immunofluorescence was
performed using anti-GR
and antiphospho-JNK (A) or
antitotal JNK (B) antibodies.
GRwt- or GRdim-express-
ing cells were first identified
with the anti-GR antibody
(arrows) and were then ana-
lyzed for phospho-JNK or to-
tal JNK immunostaining by
confocal microscopy. Bars,
15 mm.
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of active enzyme in the cytosol of stimulated cells suggests
there may be other, unidentified substrates in this com-
partment. The inhibition of JNK activity by Dex in cytosol
and nucleus also indicates the attenuation of stress-acti-
vated cytosolic pathways.
In two-hybrid experiments in yeast and in vitro, May et al.
(1998) reported that the interaction between JNK and c-Jun
does not require JNK catalytic activity. Interestingly, a
regulated inhibitory domain in the NH2-terminal region (d
domain) of c-Jun binding a putative d inhibitor that could
block its activation by JNK has been predicted (Baichwal
and Tjian, 1990). The finding that JNK binds the d domain
in resting cells led to the hypothesis that JNK itself could
be a form of this d inhibitor (Dai et al., 1995). Our results
show that Dex inhibits c-Jun phosphorylation and activa-
tion without affecting the accumulation of JNK in the nu-
cleus. Therefore, though a direct JNK-c-Jun interaction in
Dex-treated cells has not been found, our data support the
hypothesis that inactive JNK may behave as a d inhibitor,
thus preventing AP-1 activation. JNK activation is be-
lieved to contribute to inflammatory responses (Ip and
Davis, 1998), which, together with the recent finding that
c-Jun phosphorylation is critical for stress-induced apopto-
sis and cellular proliferation in vivo (Behrens et al., 1999),
and the implication of JNK in the control of p53 stability
(Fuchs et al., 1998), suggests an important physiological
role of JNK inhibition by glucocorticoids.
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